Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19023831 | 0.85 | FUCA1 (0.46) | RECQLSMN1; SMN2ALDH1A1DRD2MEN1 | |
| SCHEMBL19023830 | 0.85 | FUCA1 (0.46) | RECQLSMN1; SMN2ALDH1A1DRD2MEN1 | |
| SCHEMBL20875293 | 0.85 | FUCA1 (0.46) | RECQLSMN1; SMN2ALDH1A1DRD2MEN1 | |
| SCHEMBL4181243 | 0.82 | RECQL (0.46) | RECQLSMN1; SMN2ALDH1A1DRD2MEN1 | |
| SCHEMBL11413096 | 0.79 | FUCA1 (0.60) | ALDH1A1DRD2DRD3CYP2D6FUCA1 | |
| SCHEMBL4193483 | 0.78 | RECQL (0.48) | RECQLSMN1; SMN2ALDH1A1DRD2MEN1 | |
| SCHEMBL26709646 | 0.78 | RECQL (0.48) | RECQLSMN1; SMN2ALDH1A1DRD2MEN1 | |
| SCHEMBL16837173 | 0.77 | FUCA1 (0.58) | DRD2DRD3CYP2D6FUCA1ACHE | |
| SCHEMBL4191012 | 0.76 | FUCA1 (0.50) | ALDH1A1DRD2DRD3CYP2D6FUCA1 | |
| SCHEMBL4198217 | 0.76 | FUCA1 (0.54) | ALDH1A1DRD2DRD3FUCA1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | RECQL 1918/4885SMN1; SMN2 2082/4885ALDH1A1 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.